A healthcare tracking poll finds unhappiness aimed at the drug industry for high drug prices while more Americans are warming up to the idea of a national health plan; a study says opioid overdose deaths are undercounted by as much as 35%; whole-genome sequencing may not drive up downstream medical costs, but questions about its use remain.
A poll from the Kaiser Family Foundation found that 72% of Americans think the drug industry has too much influence in Washington, Kaiser Health News reported. In addition, more people are taking to the notion of a national health plan. Overall, 59% said they supported it; that percentage rose to 75% if such a plan was presented as 1 option among others to choose from.
Standards for how to investigate and report on overdoses vary widely across states and counties, NPR reported, leading to an undercounting of opioid overdose deaths. The country is undercounting opioid-related overdoses by 20% to 35%, according to a recent study in the journal Addiction. Local coroners and medical examiners send data from death certificates to state offices, eventually landing at the CDC, which reported that more than 42,000 people died from opioid-related overdoses in 2016. The author of the study said the real number is likely closer to 50,000.
Will whole-genome sequencing drive up downstream costs? A study reported in STAT indicated that could be a possibility, although questions remain. Healthy volunteers who had genome sequencing incurred slightly higher medical costs of $3670, on average, compared with $2989 for those who had just a basic family medical history. Some issues raised include how providers who are not experienced in genetics or statistics will understand the results without practicing defensive medicine, as well as the nation’s shortage of genetic counselors.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More